Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. (1st September 2016)

• Record Type: Journal Article
• Authors: Tuñón, José; Barbas, Coral; Blanco-Colio, Luis; Burillo, Elena; Lorenzo, Óscar; Martín-Ventura, José Luis; Más, Sebastián; Rupérez, Francisco Javier; Egido, Jesús
• Is Part Of: Expert review of proteomics. Volume 13:Number 9(2016)
• Page Start: 857
• Page End: 871
• Publication Date: 2016-09-01
• Subjects: Cardiovascular disease -- biomarkers -- proteomics -- metabolomics -- therapeutic targets -- atherothrombosis; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2016.1217775
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction: The process of discovering novel biomarkers and potential therapeutic targets may be shortened using proteomic and metabolomic approaches. Areas c overed: Several complementary strategies, each one presenting different advantages and limitations, may be used with these novel approaches. In vitro studies show how cells involved in cardiovascular disease react, although the phenotype of cultured cells differs to that occurring in vivo . Tissue analysis either in human specimens or animal models may show the proteins that are expressed in the pathological process, although the presence of structural proteins may be confounding. To identify circulating biomarkers, analyzing the secretome of cultured atherosclerotic tissue, analysis of blood cells and/or plasma may be more straightforward. However, in the latter approach, high-abundant proteins may mask small molecules that could be potential biomarkers. The study of sub-proteomes such as high-density lipoproteins may be useful to circumvent this limitation. Regarding metabolomics, most studies have been performed in small populations, and we need to perform studies in large populations in order to discover robust biomarkers. Expert commentary: It is necessary to involve the clinicians in these areas to improve the design of clinical studies, including larger populations, in order to obtain consistent novel biomarkers.